HORMONE RECEPTOR POSITIVE TUMOR
Clinical trials for HORMONE RECEPTOR POSITIVE TUMOR explained in plain language.
Never miss a new study
Get alerted when new HORMONE RECEPTOR POSITIVE TUMOR trials appear
Sign up with your email to follow new studies for HORMONE RECEPTOR POSITIVE TUMOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Radio waves vs. breast cancer: new device tested before surgery
Disease control Recruiting nowThis study tests whether a device called TheraBionic P1, which delivers targeted radio waves, can help shrink early-stage breast cancer before surgery. About 24 women with hormone receptor-positive, HER2-negative breast cancer will use the device daily for a short time before the…
Matched conditions: HORMONE RECEPTOR POSITIVE TUMOR
Phase: NA • Sponsor: Barbara Ann Karmanos Cancer Institute • Aim: Disease control
Last updated May 26, 2026 03:16 UTC
-
New hope for advanced breast cancer: targeted drug combo tested in phase 3 trial
Disease control Recruiting nowThis study tests whether a new drug, RLY-2608, combined with fulvestrant works better than another drug combo (capivasertib + fulvestrant) for people with a specific genetic mutation (PIK3CA) in advanced hormone-receptor-positive, HER2-negative breast cancer. About 540 adults who…
Matched conditions: HORMONE RECEPTOR POSITIVE TUMOR
Phase: PHASE3 • Sponsor: Relay Therapeutics, Inc. • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
New pill aims to shrink tumors in advanced breast and ovarian cancers
Disease control Recruiting nowThis study tests a new daily pill, INX-315, in 150 people with advanced breast, ovarian, or other solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe and can shrink or control tumors. The study includes three parts: testing the…
Matched conditions: HORMONE RECEPTOR POSITIVE TUMOR
Phase: PHASE1, PHASE2 • Sponsor: Incyclix Bio • Aim: Disease control
Last updated May 20, 2026 11:57 UTC
-
New pill targets Hard-to-Treat cancers with PIK3CA mutation
Disease control Recruiting nowThis early-phase study tests an experimental oral drug, RGT-490, in adults with advanced solid tumors (including breast, ovarian, and endometrial cancers) that have a specific genetic change called PIK3CA. The main goals are to check safety, find the right dose, and see if the dr…
Matched conditions: HORMONE RECEPTOR POSITIVE TUMOR
Phase: PHASE1 • Sponsor: Regor Pharmaceuticals Inc. • Aim: Disease control
Last updated May 20, 2026 11:55 UTC
-
New drug combo shows promise in shrinking breast tumors before surgery
Disease control Recruiting nowThis study is for premenopausal women with a common type of breast cancer (HR+/HER2-). It tests a drug called elacestrant, given alone or with another drug (triptorelin), for 4 weeks before surgery. The goal is to see if the treatment lowers a marker of cancer growth (Ki67) in th…
Matched conditions: HORMONE RECEPTOR POSITIVE TUMOR
Phase: PHASE2 • Sponsor: SOLTI Breast Cancer Research Group • Aim: Disease control
Last updated May 18, 2026 12:07 UTC
-
Breast cancer trial aims to match drugs to tumors with High-Tech imaging
Knowledge-focused Recruiting nowThis study is testing whether adding new experimental drugs to standard chemotherapy before surgery can improve outcomes for people with breast cancer. It includes up to 5,000 participants with early-stage or locally advanced breast cancer. The goal is to use MRI scans and tissue…
Matched conditions: HORMONE RECEPTOR POSITIVE TUMOR
Phase: PHASE2 • Sponsor: QuantumLeap Healthcare Collaborative • Aim: Knowledge-focused
Last updated May 22, 2026 13:54 UTC
-
New study tracks Pill-Taking habits in early breast cancer patients
Knowledge-focused Recruiting nowThis study looks at how well women with early-stage, hormone-positive breast cancer take their prescribed medications (aromatase inhibitors with or without abemaciclib). About 319 participants will be followed for 6 months to see if those on the combination therapy have lower adh…
Matched conditions: HORMONE RECEPTOR POSITIVE TUMOR
Sponsor: Institute of Oncology Ljubljana • Aim: Knowledge-focused
Last updated May 18, 2026 12:12 UTC